NASDAQ:TNYA Tenaya Therapeutics (TNYA) Stock Price, News & Analysis $0.43 0.00 (-1.03%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.44 +0.00 (+1.07%) As of 05/23/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Tenaya Therapeutics Stock (NASDAQ:TNYA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Tenaya Therapeutics alerts:Sign Up Key Stats Today's Range$0.39▼$0.4450-Day Range$0.39▼$0.7052-Week Range$0.36▼$4.60Volume1.80 million shsAverage Volume2.48 million shsMarket Capitalization$70.01 millionP/E RatioN/ADividend YieldN/APrice Target$6.25Consensus RatingBuy Company OverviewTenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Read More… Tenaya Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreTNYA MarketRank™: Tenaya Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 358th out of 918 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingTenaya Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTenaya Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Tenaya Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Tenaya Therapeutics are expected to grow in the coming year, from ($1.35) to ($1.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tenaya Therapeutics is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tenaya Therapeutics is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTenaya Therapeutics has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.51% of the float of Tenaya Therapeutics has been sold short.Short Interest Ratio / Days to CoverTenaya Therapeutics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tenaya Therapeutics has recently decreased by 0.46%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTenaya Therapeutics does not currently pay a dividend.Dividend GrowthTenaya Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.51% of the float of Tenaya Therapeutics has been sold short.Short Interest Ratio / Days to CoverTenaya Therapeutics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tenaya Therapeutics has recently decreased by 0.46%, indicating that investor sentiment is improving. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Tenaya Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 14 people have searched for TNYA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows12 people have added Tenaya Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership5.0 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Tenaya Therapeutics insiders have bought 179,730.23% more of their company's stock than they have sold. Specifically, they have bought $24,999,999.00 in company stock and sold $13,902.00 in company stock.Percentage Held by Insiders32.76% of the stock of Tenaya Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions90.54% of the stock of Tenaya Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tenaya Therapeutics' insider trading history. Receive TNYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tenaya Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TNYA Stock News HeadlinesBrokerages Set Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Target Price at $6.25May 21, 2025 | americanbankingnews.comTenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)May 16, 2025 | finanznachrichten.deThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?May 25, 2025 | Timothy Sykes (Ad)Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)May 15, 2025 | globenewswire.comTenaya Therapeutics to Present Five Abstracts on Innovative Heart Disease Gene Therapies at ASGCT 2025 Annual MeetingMay 15, 2025 | nasdaq.comTenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual MeetingMay 13, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Vigil Neuroscience Inc (VIGL), Stevanato Group (STVN) and Tenaya Therapeutics (TNYA)May 11, 2025 | theglobeandmail.comWe're A Little Worried About Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn RateMay 10, 2025 | finance.yahoo.comSee More Headlines TNYA Stock Analysis - Frequently Asked Questions How have TNYA shares performed this year? Tenaya Therapeutics' stock was trading at $1.43 at the beginning of the year. Since then, TNYA stock has decreased by 69.9% and is now trading at $0.4304. View the best growth stocks for 2025 here. How were Tenaya Therapeutics' earnings last quarter? Tenaya Therapeutics, Inc. (NASDAQ:TNYA) announced its quarterly earnings results on Wednesday, May, 7th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by $0.06. When did Tenaya Therapeutics IPO? Tenaya Therapeutics (TNYA) raised $150 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. Who are Tenaya Therapeutics' major shareholders? Top institutional shareholders of Tenaya Therapeutics include Woodline Partners LP (6.75%), AQR Capital Management LLC (0.89%), Nuveen LLC (0.26%) and Goldman Sachs Group Inc. (0.24%). Insiders that own company stock include Group Gp Lp Column III, David V Goeddel, Deepak Srivastava, Faraz Ali, Timothy Hoey, Whittemore Tingley, Tomohiro Higa and Chihiro Saito. View institutional ownership trends. How do I buy shares of Tenaya Therapeutics? Shares of TNYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tenaya Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tenaya Therapeutics investors own include Voyager Therapeutics (VYGR), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings5/07/2025Today5/24/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TNYA CIK1858848 Webwww.tenayatherapeutics.com Phone650-825-6990FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Stock Price Target$6.25 High Stock Price Target$9.00 Low Stock Price Target$5.00 Potential Upside/Downside+1,352.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-124,080,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-86.17% Return on Assets-71.14% Debt Debt-to-Equity RatioN/A Current Ratio5.27 Quick Ratio5.27 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.05 per share Price / Book0.21Miscellaneous Outstanding Shares162,667,000Free Float53,268,000Market Cap$70.01 million OptionableOptionable Beta2.99 20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free Report This page (NASDAQ:TNYA) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenaya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenaya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.